Innovent Announces Phase Ib Results of Higher-dose Mazdutide (IBI362) in Chinese Participants with Overweight or Obesity Published in eClinicalMedicine

PR Newswire
October 17, 2022 — 08:00 CST

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Related Topics: Casino China chinese Economy Education healthcare Hong Kong Macau manufacturing medicine stock exchange stock market Suzhou taiwan United States University

Related News:

Goodstack Unveils its All-in-One Impact Suite to Transform Corporate Giving and Social Impact

April 23, 2025 — 02:17

TRICORBRAUN APPOINTS KEVIN WEADICK AS PRESIDENT AND CEO

April 23, 2025 — 01:30

China High Speed Transmission Equipment Group Commences Legal Proceedings for Fund Misappropriation of RMB 6.64 Billion

April 1, 2025 — 12:31

Luye Pharma’s Rivastigmine Twice Weekly Transdermal Patch Approved for Marketing in Japan for the Treatment of Alzheimer’s Dementia

March 31, 2025 — 21:35

Xinhua Silk Road: Parallel Forum on Inclusive Finance and Approaches to New Energy Industrialization Development held in Beijing

March 22, 2025 — 20:08

Lion Announces Plan to Implement ADS Ratio Change

March 22, 2025 — 04:05

Pre-registrations for Ragnarok: Back to Glory is now live! BOW Maylada, together with the grand prize worth US$77,777, invites you to join the battle of glory!

March 21, 2025 — 15:19

Wingderm® Presents at the 2025 AAD Annual Meeting, Strengthening Its Presence in the North American Market

March 11, 2025 — 01:00

APAC Hiring Intentions Strengthen as Employers Express Optimism for Q2 2025

March 11, 2025 — 00:01

Franchising and Licensing Asia (FLAsia) 2024